antibody-drug conjugates

News

AZ, Daiichi get FDA nod for Dato-DXd in breast cancer

AstraZeneca and Daiichi Sankyo have claimed FDA approval for a second antibody-drug conjugate for breast cancer - TROP2-directed Datroway.

News

GSK bags breakthrough status for bone cancer drug

GSK has claimed its second breakthrough designation from the FDA for B7-H3-targeted ADC, this time in osteosarcoma.

News

Daiichi and AZ pull Dato-DXd filing in Europe too

AstraZeneca and Daiichi Sankyo have decided to voluntarily withdraw their EU marketing application for Dato-DXd in lung cancer.

News

Gilead looks beyond Trodelvy with Tubulis alliance

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415m.

News

Kelun's MSD-partnered TROP2 drug gets first okay in China

Kelun-Biotech has become the second drugmaker to bring a TROP2 ADC to regulatory approval, after its sac-TMT drug was cleared in China

News

WCLC: MSD/Daiichi build case for phase 3 ADC for lung cancer

MSD and Daiichi Sankyo have revealed some of the clinical data that prompted them to start pivotal testing of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-st

AZ, Daiichi get FDA nod for Dato-DXd in breast cancer

GSK bags breakthrough status for bone cancer drug

Daiichi and AZ pull Dato-DXd filing in Europe too

Gilead looks beyond Trodelvy with Tubulis alliance

Kelun's MSD-partnered TROP2 drug gets first okay in China

WCLC: MSD/Daiichi build case for phase 3 ADC for lung cancer

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

antibody-drug conjugates

Editor's Picks